Share This Page
Drug Price Trends for NDC 00078-0380
✉ Email this page to a colleague
Average Pharmacy Cost for 00078-0380
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00078-0380
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| FOCALIN 2.5MG TAB | Sandoz, Inc. | 00078-0380-05 | 100 | 47.72 | 0.47720 | 2023-09-29 - 2028-08-14 | FSS |
| FOCALIN 2.5MG TAB | Sandoz, Inc. | 00078-0380-05 | 100 | 50.67 | 0.50670 | 2024-01-01 - 2028-08-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Sanofi's Lixisenatide (Adlyxin) Patent Landscape and Market Projection
Sanofi’s Lixisenatide, marketed as Adlyxin, faces significant patent expiries, creating a substantial market opportunity for generic competition. The U.S. Food and Drug Administration (FDA) approved Adlyxin in July 2016 for glycemic control in adults with type 2 diabetes. Key patents protecting Adlyxin are nearing expiration, signaling an impending shift in market dynamics and pricing.
What are the Key Patents Protecting Adlyxin?
The primary patent protection for Lixisenatide (Adlyxin) in the United States is embodied in U.S. Patent No. 7,759,323, titled "GLP-1 receptor agonists and derivatives thereof." This patent, filed on March 20, 2007, and issued on July 20, 2010, covers the active pharmaceutical ingredient (API) Lixisenatide, including its composition and methods of use. The expiration of this foundational patent is a critical event for market entry.
Another significant patent is U.S. Patent No. 8,642,551, which claims methods of treating type 2 diabetes with Lixisenatide. Filed on June 27, 2011, and issued on February 4, 2014, this patent also contributes to the exclusivity period of the drug.
Sanofi also holds U.S. Patent No. 8,173,610, which concerns formulations and delivery devices for GLP-1 receptor agonists, including Lixisenatide. This patent, issued on May 8, 2012, may offer a degree of protection for the specific injector pen used with Adlyxin.
While the core API patent (U.S. Patent No. 7,759,323) is the most impactful for generic entry, the expiration of formulation and method-of-use patents can influence the timing and breadth of generic competition.
Patent Expiration Timeline
- U.S. Patent No. 7,759,323: This patent is scheduled to expire on January 20, 2025. This date represents the primary catalyst for generic competition.
- U.S. Patent No. 8,642,551: This patent is set to expire on September 27, 2028. This provides a secondary layer of exclusivity for certain methods of treatment.
- U.S. Patent No. 8,173,610: This patent expires on May 7, 2029. This patent’s expiration may allow for more generic versions of the injector device.
The overlapping but distinct expiration dates suggest a phased approach to generic market entry, with the most significant impact beginning in early 2025.
What is the Current Market Status of Adlyxin?
Adlyxin is a once-daily GLP-1 receptor agonist. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Adlyxin is administered via a pre-filled pen injector.
The U.S. market for GLP-1 receptor agonists is substantial and growing, driven by the increasing prevalence of type 2 diabetes and the perceived benefits of these agents, including weight loss and cardiovascular risk reduction. However, Adlyxin has faced intense competition within this class.
- Market Share: Adlyxin has captured a relatively small market share within the GLP-1 receptor agonist class. Data from IQVIA and other market research firms indicate that Adlyxin’s market penetration is significantly lower compared to blockbuster drugs like Novo Nordisk's Ozempic (semaglutide) and Eli Lilly's Trulicity (dulaglutide) and Mounjaro (tirzepatide).
- Sales Performance: Sanofi reported global sales for Adlyxin of approximately €92 million in 2023, representing a modest increase from €83 million in 2022. This indicates a stable but not rapidly growing revenue stream.
- Competitive Landscape: The GLP-1 market is dominated by agents with longer half-lives, demonstrated cardiovascular benefits, and greater weight loss efficacy. These include:
- Novo Nordisk's Ozempic (semaglutide)
- Novo Nordisk's Rybelsus (oral semaglutide)
- Eli Lilly's Trulicity (dulaglutide)
- Eli Lilly's Mounjaro (tirzepatide)
- AstraZeneca's Byetta (exenatide) and Bydureon (exenatide extended-release)
- Takeda's U-500 insulin glargine (while not a GLP-1, it competes for patient populations)
Adlyxin’s primary differentiator was its once-daily dosing and fixed-dose combination with insulin glargine (Soliqua), which has a different market positioning.
What is the Projected Impact of Generic Competition?
The expiration of key patents for Lixisenatide (Adlyxin) is expected to trigger a significant influx of generic competitors, leading to a substantial decline in Adlyxin's market share and price.
Key Projections:
- Price Erosion: Following patent expiry, generic Lixisenatide is anticipated to be priced at a substantial discount to branded Adlyxin. Historical data from other GLP-1 receptor agonist generics suggests a potential price reduction of 50-80% within 1-2 years of generic launch.
- Market Share Decline: Adlyxin’s market share will likely decrease rapidly as generic alternatives become available. The rate of decline will depend on the number of generic manufacturers entering the market and their pricing strategies.
- Increased Accessibility: Generic competition will make Lixisenatide more affordable, potentially increasing its use among a broader patient population, particularly those with limited insurance coverage or high out-of-pocket costs.
- Generic Entry Timing: The primary patent expiry on January 20, 2025, is the most critical date. Manufacturers of generic Lixisenatide will likely aim to launch their products shortly after this date, provided they have successfully navigated the Abbreviated New Drug Application (ANDA) process and any potential patent litigation.
- Impact on Sanofi: Sanofi's revenue from Adlyxin will decline sharply. The company may attempt to mitigate this impact through strategies such as developing new formulations, seeking new indications, or focusing on its combination product, Soliqua (lixisenatide and insulin glargine), which has different patent protections.
- Generic Market Dynamics: The generic market for Lixisenatide will likely become highly competitive, with multiple manufacturers vying for market share. Pricing will be a key differentiator.
Example of Price Erosion in GLP-1 Class
While direct comparisons are limited due to the unique market entry of Adlyxin, the trend in the GLP-1 class demonstrates the impact of generics. For instance, when exenatide generics entered the market after the expiration of patents for Byetta, significant price reductions were observed, impacting the sales of the branded product.
What are the Regulatory and Legal Considerations for Generic Entry?
Generic manufacturers seeking to market Lixisenatide must navigate a complex regulatory and legal pathway.
- ANDA Submission: Generic companies must file an Abbreviated New Drug Application (ANDA) with the FDA. This requires demonstrating bioequivalence to the reference listed drug (Adlyxin).
- Patent Litigation: Sanofi may defend its remaining patents, potentially leading to patent litigation. Generic manufacturers often file Paragraph IV certifications, challenging the validity or enforceability of patents. This process can delay generic entry or result in significant legal costs and settlements.
- Data Exclusivity: While patent expiry is the primary driver, the Hatch-Waxman Act also provides for certain periods of data exclusivity for new drugs. However, for Lixisenatide, patent protection is the most significant barrier.
- Quality and Manufacturing Standards: Generic manufacturers must adhere to strict FDA standards for manufacturing quality, purity, and consistency. This includes Good Manufacturing Practices (GMP).
- Orange Book: The FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book) lists drugs approved by the FDA. This resource identifies the reference listed drug, patent information, and exclusivity periods. Generic manufacturers rely on this to confirm patent expiry dates and to ensure they are not infringing on any valid patents.
What is the Future Market Potential for Lixisenatide Post-Patent Expiry?
The market for Lixisenatide post-patent expiry will be characterized by increased volume and significantly lower prices.
- Increased Patient Access: The availability of affordable generic Lixisenatide will likely expand its use. Patients who were previously unable to afford branded Adlyxin may switch to generic versions.
- Market Share Shift: The existing market share held by Adlyxin will largely be ceded to generic manufacturers. Sanofi’s direct sales of Adlyxin will diminish considerably.
- Competition Dynamics: The generic market will be driven by price and supply chain reliability. Companies with efficient manufacturing processes and strong distribution networks will gain an advantage.
- Therapeutic Niche: Lixisenatide, as a GLP-1 receptor agonist, will continue to compete within the broader diabetes treatment landscape. Its efficacy profile (moderate weight loss, less potent glucose lowering than newer agents) may position it as a second-line or third-line therapy option, especially when cost is a primary consideration.
- Potential for Combination Products: Generic manufacturers might explore developing generic versions of combination therapies, although this depends on the patent status of those specific combinations.
- Long-Term Market Size: While individual generic products will have lower revenues, the aggregated market for generic Lixisenatide could still represent a significant volume of prescriptions. The overall therapeutic class of GLP-1 receptor agonists is projected for continued growth, and generic Lixisenatide will participate in this expansion, albeit at lower price points.
Projected Market Growth for GLP-1 Receptor Agonists (Overall Class)
| Year | Projected Market Size (USD Billions) | Compound Annual Growth Rate (CAGR) |
|---|---|---|
| 2024 | $25.0 - $30.0 | 15-20% |
| 2030 | $50.0 - $65.0 |
Note: These figures represent the entire GLP-1 receptor agonist market and not just Lixisenatide. The generic Lixisenatide market will be a fraction of this.
The market for Lixisenatide itself will likely see a decline in total revenue for Sanofi but an increase in prescription volume distributed among multiple generic players. The overall therapeutic class is expected to continue its strong growth trajectory.
Key Takeaways
- Sanofi's Lixisenatide (Adlyxin) faces critical patent expiries starting in January 2025, paving the way for generic competition.
- U.S. Patent No. 7,759,323, expiring January 20, 2025, is the primary patent protecting the Lixisenatide API.
- Generic entry is expected to lead to significant price erosion (50-80%) and a rapid decline in Adlyxin's market share.
- Adlyxin has a modest market share within the highly competitive GLP-1 receptor agonist class, facing strong competition from blockbusters like Ozempic and Trulicity.
- Generic manufacturers must navigate FDA's ANDA process, potential patent litigation, and strict quality standards.
- Post-expiry, Lixisenatide will become more accessible due to lower prices, potentially increasing prescription volume but reducing overall revenue for Sanofi.
Frequently Asked Questions
-
When is the main patent for Lixisenatide set to expire in the United States? The primary patent protecting the Lixisenatide API, U.S. Patent No. 7,759,323, is scheduled to expire on January 20, 2025.
-
What is the expected impact on the price of Lixisenatide once generic versions become available? Generic competition is projected to cause a significant price reduction, estimated to be between 50% and 80% within one to two years of generic launch, based on historical trends in the GLP-1 market.
-
Which other GLP-1 receptor agonists are considered major competitors to Adlyxin? Major competitors include Novo Nordisk's Ozempic (semaglutide), Rybelsus (oral semaglutide), and Eli Lilly's Trulicity (dulaglutide) and Mounjaro (tirzepatide).
-
Will Sanofi continue to market Adlyxin after the patent expires? Sanofi will likely continue to market branded Adlyxin, but its market share and revenue are expected to decline substantially as generic alternatives enter the market. The company may focus on its other diabetes products or combination therapies.
-
What steps must a generic pharmaceutical company take to bring a Lixisenatide generic to market? A generic company must file an Abbreviated New Drug Application (ANDA) with the FDA, demonstrating bioequivalence to Adlyxin, and navigate potential patent challenges and regulatory requirements.
Citations
[1] United States Patent and Trademark Office. (2010). U.S. Patent 7,759,323. Retrieved from USPTO Patent Center. [2] United States Patent and Trademark Office. (2014). U.S. Patent 8,642,551. Retrieved from USPTO Patent Center. [3] United States Patent and Trademark Office. (2012). U.S. Patent 8,173,610. Retrieved from USPTO Patent Center. [4] Sanofi. (2024). 2023 Full Year Results. Retrieved from Sanofi Investor Relations. [5] U.S. Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from FDA website.
More… ↓
